Overview

A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer

Status:
Terminated

Trial end date:
2014-09-01

Target enrollment:

Participant gender:

Summary

Small cell lung cancer is an aggressive neuroendocrine tumour that often presents with extensive (metastatic) disease. Chemotherapy is the mainstay of treatment, with radiotherapy to the primary tumour. It is now part of care to also offer Prophylactic Cranial Irradiation (PCI) in order to prevent spread of the cancer into the brain. Cognitive impairment can result after cranial irradiation. Lithium is thought to be neuroprotective. It is hypothesized that lithium administration with PCI will be safe, tolerable and feasible, and can be studied to prevent or ameliorate the ensuing cognitive impairment.

Phase:

N/A

Details

Lead Sponsor:

Barwon Health

Collaborators:

Deakin University
Peter MacCallum Cancer Centre, Australia

Treatments:

Lithium Carbonate
Neuroprotective Agents